Analysts’ Perspective: Assembly Biosciences (ASMB), Lemaitre Vascular (LMAT), Willis Towers Watson (WLTW)

Investment Analysts at B. Riley FBR upgrade Assembly Biosciences, Inc. (NASDAQ:ASMB) shares from Neutral to Buy rating with a price target of $42.

Assembly Biosciences, Inc. operates as a clinical stage biotechnology company.


Brokerage Firm Barrington Research upgraded Lemaitre Vascular, Inc. (NASDAQ:LMAT) shares from Market Perform to Outperform rating with a price target of $34.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.


Willis Towers Watson Public Limited Company (NASDAQ:WLTW) shares were upgraded by analysts at Credit Suisse from Neutral to Outperform rating.

Willis Towers Watson Public Limited Company operates as an advisory, broking, and solutions company worldwide.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at